Skip to content
‹ Back to IndustriesHealthcare

Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and that can be difficult because UV-C is, in practical terms, an invisible tool.

Since the beginning of the pandemic, the world is acutely aware that infection control isn’t just for hospitals. Discussing these new use cases and how UV-C works, host Daniel Litwin spoke with Wendy Brady, Director of Global Marketing for Intellego Technologies.

“Pathogens are everywhere on the surfaces we touch and the air we breathe. UV-C can be an important tool to protect spaces outside of healthcare,” Brady said. But the key to successful UV-C disinfection is ensuring that you’ve delivered the right amount of ultraviolet irradiation to surfaces.

So, how exactly does UV-C light work?

“UV-C is part of the ultraviolet spectrum and it has a powerful germicidal effect on bacteria, viruses and fungi,” Brady explained. “The way it works is by breaking the DNA or RNA bonds in organisms so they can then no longer reproduce. It renders them inactive, but a sufficient amount of energy or irradiation must be delivered to surface in order to achieve a germicidal effect.”

With established and widespread use in hospitals, other industries are now looking to the technology to help combat pathogens and make public areas safer. Brady said that schools, airports, hotels, event venues, commercial office buildings and more are all beginning to employ different types of UV-C systems to provide a higher level of sanitization.

Because UV-C is often used in unoccupied spaces or in closed cabinet systems, it’s challenging for operators to know if their device is truly working and that all target areas have received enough irradiation to achieve sanitization. It’s not something they can see, but dosimeters provide that important piece of visible evidence.

“UVC Dosimeters have a color-changing indicator area that shows the ‘dose’ or how much germicidal irradiation has been delivered. By seeing the dose, measured as 25, 50 or 100 mJ/cm², a person can verify that the device has delivered enough energy needed to kill SARS-CoV-2, MRSA or even C. Difficile,” Brady said.

With a dosimeter, users have accurate, visible confirmation and real-time evidence that a UV-C disinfection device has done its job. With this additional context, disinfecting can become a more efficient process and it builds confidence in the effectiveness of the technology.

“Dosimeters can also save time, as users can see when the disinfection cycle is successful. Operators are finding that some areas can be sanitized more quickly than expected because they can see when they’ve reached a target dose. This means they can use their UV-C equipment in a more efficient manner, sanitizing more areas and creating safer environments,” Brady added.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agreed to acquire most of Vantive's hemodialysis business for $125 million in base consideration, plus up to $45 million in contingent payments, with closing expected mid-2027. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility; the combined business could generate $400-450 million annually, depending on various factors.

  • 01Rockwell Medical acquires Vantive's hemodialysis concentrates, AK 98 machines, water treatment systems, and one-million-square-foot Medolla, Italy manufacturing campus for $125 million base price plus up to $45 million contingent on revenue and EBITDA milestones.
  • 02Combined business targeted to generate $400-450 million in annual revenue depending on operating performance, exchange rates, market conditions and integration.
  • 03Vantive's dialyzer portfolio, including Theranova dialyzer for expanded hemodialysis, remains with Vantive; the company will focus on home dialysis and critical care after divestiture.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512